Efficacy and safety of dapsone gel 5% for the treatment of acne vulgaris in adolescents

Cutis

Volumn 81, Issue 2, 2008, Pages 171-178

  Raimer, Sharon ^a,b   Maloney, J Michael ^a,c   Bourcier, Marc ^a,d   Wilson, David ^a,e   Papp, Kim ^a,f,g   Siegfried, Elaine ^a,h   Garrett, Steven ^a,i  

^a Canada Dapsone Gel Study Group   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Cherry Creek Orthopaedic Specialists   (United States)

^d Nephrology Progamme   (Canada)

^e Education and Research Foundation   (United States)

^f PROBITY MEDICAL RESEARCH   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h Kids Dermatology   (United States)

ⁱ QLT USA Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; FOLIC ACID ANTAGONIST;

ACNE VULGARIS; ADOLESCENT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GEL; HUMAN; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; UNITED STATES;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ADOLESCENT; CANADA; DAPSONE; DOUBLE-BLIND METHOD; FEMALE; FOLIC ACID ANTAGONISTS; GELS; HUMANS; MALE; TREATMENT OUTCOME; UNITED STATES;

EID: 41149092945     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Weiss JS. Current options for the topical treatment of acne vulgaris. Pediatr Dermatol. 1997;14:480-488.
2. Bergfeld WF. The pathophysiology of acne vulgaris in children and adolescents, part 1. Cutis. 2004;74:92-97.
3. McConnell RC, Fleischer AB Jr, Williford PM, et al. Most topical tretinoin treatment is for acne vulgaris through the age of 44 years: an analysis of the National Ambulatory Medical Care Survey, 1990-1994. J Am Acad Dermatol. 1998;38:221-226.
4. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol. 2003;19:1-10.
5. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20-27.
6. Holland DB, Jeremy AH, Roberts SG, et al. Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar, Br J Dermatol. 2004;150:72-81.
7. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420-434.
8. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis, report of three cases. J Am Acad Dermatol. 1987;16:772-778.
9. Ross CM. The treatment of acne vulgaris with dapsone. Br} Dermatol. 1961;73:367-370.
10. Kaminsky CA, de Kaminsky AR, Schicci C, et al. Acne: treatment with diaminodiphenylsulfone. Cutis. 1974;13:869-871.
11. Bluhm RE, Adedoyin A, McCarver DG, et al. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors. Clin Pharmacol Ther. 1999;65:598-605.
12. Ciccoli L, Ferrali M, Rossi V, et al. Hemolytic drugs aniline and dapsone induce iron release in erythrocytes and increase the free iron pool in spleen and liver. Toxicol Lett. 1999;110:57-66.
13. Jollow DJ, Bradshaw TP, McMillan DC. Dapsone-induced hemolytic anemia. Drug Metab Rev. 1995;27:107-124.
14. Luckt AW, Maloney JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long-term (1 year) treatment. J Drug Dermatol. 2007;6:981-987.
15. Draelos ZD, Carter E, Maloney JM, et al; United States/Canada Dapsone Gel Study Group. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. ] Am Acad Dermatol. 2007;56:439.e1-e10.
16. Thiboutot D, Willmer J, Sharata H, et al. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007;46:697-712.
17. Cunliffe WJ, Poncet M, Lowsche C, et al. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139(suppl 52):48-56.
18. Benzaclin Topical Gel [package insert]. Berwyn, PA: Dermik Laboratories; 2003.
19. Duac Topical Gel [package insert]. Coral Gables, FL: Stiefel Laboratories, Inc; 2003.
20. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20-27.
21. Haider A, Shaw JC. Treatment of acne vulgaris. JAMA. 2004;292:726-735.
22. Matsui DM. Drug compliance in pediatrics, clinical and research issues. Pediatr Clin North Am. 1997;44:1-14.